4.1 Article

Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials

期刊

ADDICTION BIOLOGY
卷 27, 期 2, 页码 -

出版社

WILEY
DOI: 10.1111/adb.13130

关键词

alcohol use disorder; heavy drinkers; pharmacogenetic analysis; post-treatment follow-up; topiramate

资金

  1. U.S. Department of Veterans Affairs
  2. Mental Illness Research, Education and Clinical Center of the Veterans Integrated Service Network 4
  3. NIAAA [P60 AA03510, R01 AA023192, R01 AA025539]

向作者/读者索取更多资源

Topiramate reduces drinking and alcohol-related problems during treatment, but the effects diminish significantly after discontinuation. The rs2832407, a single nucleotide polymorphism (SNP) in the GRIK1 gene, does not significantly moderate the treatment outcomes.
Topiramate reduces drinking and alcohol-related problems and is increasingly being used to treat alcohol use disorder (AUD). In a randomized controlled trial (RCT) of topiramate, rs2832407, a single nucleotide polymorphism (SNP) in the GRIK1 gene moderated topiramate's effects (Study 1). However, a second RCT (Study 2) did not replicate the SNP's moderating effect during treatment. The current analysis combines data from these two studies to examine topiramate's effects on alcohol-related outcomes and on its pharmacogenetic moderation during a 6-month post-treatment period. This analysis includes 308 individuals with problematic alcohol use (67% male; mean age = 51.1; topiramate: 49%, placebo: 51%). It uses generalized linear mixed models to examine changes in self-reported alcohol consumption and alcohol-related problems and concentrations of the liver enzyme gamma-glutamyltransferase. The report combines published 3- and 6-month follow-up data from Study 1 with similar, unpublished data from Study 2. Despite robust effects of topiramate on drinking during treatment, the overall multivariate medication effects on outcomes during 3- and 6-month follow-up were not significant (p = 0.08 and p = 0.26, respectively). The moderating effect of the SNP on primary treatment outcomes was also not significant during either follow-up period (p = 0.13 and p = 0.16, respectively). However, during the 3-month post-treatment period, drinks per day was significantly lower in the topiramate group than the placebo group in the rs2832407*CC-genotype group. The robust effects of topiramate on alcohol-related outcomes during treatment diminish substantially once the medication is discontinued. Research is needed both to determine the optimal treatment duration and to identify clinically useful pharmacogenetic moderators of topiramate for treating AUD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据